Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
The LancetPublished 16 June 2017
Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan Kivitz, Robert J. Moots, Zhen Luo
Citations471
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Tofacitinib monotherapy was not shown to be non-inferior to either combination of adalimumab and methotrexate, and no new or unexpected safety issues were reported for either treatment in this study for up to 1 year.
Abstract
Pfizer Inc.
Keywords
Medicine
Arthritis & Rheumatism2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
9,560 Citations2010Daniel Aletaha, Tuhina Neogi +33 more
This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Annals of the Rheumatic DiseasesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
5,775 Citations2017Josef S Smolen, Robert Landewé +47 more
These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
The LancetRheumatoid arthritis
4,742 Citations2016Josef S Smolen, Daniel Aletaha +1 more
Current insights into genetics and aetiology, pathophysiology, epidemiology, assessment, therapeutic agents, and treatment strategies together with unmet needs of patients with rheumatoid arthritis are described.
Arthritis & Rheumatology2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
2,787 Citations2015Jasvinder A. Singh, Kenneth G. Saag +24 more
Arthritis & RheumatismThe PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
1,786 Citations2005Ferdinand C. Breedveld, Michael H. Weisman +7 more
Combination therapy with adalimumab plus MTX was significantly superior to either MTX alone or ad alimumab alone in improving signs and symptoms of disease, inhibiting radiographic progression, and effecting clinical remission in patients with early, aggressive rheumatoid arthritis.
Arthritis & RheumatismAdalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
1,763 Citations2003Michael E. Weinblatt, Edward Keystone +7 more
The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.
Arthritis & RheumatismRadiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
1,171 Citations2004Edward Keystone, Arthur F. Kavanaugh +6 more
In this 52-week trial, adalimumab was more effective than placebo at inhibiting the progression of structural joint damage, reducing the signs and symptoms, and improving physical function in patients with active RA who had demonstrated an incomplete response to MTX.
Arthritis Care & Research2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
1,109 Citations2015Jasvinder A. Singh, Kenneth G. Saag +24 more
To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA), a large number of patients with RA are referred to a single clinic for treatment with these medications.
New England Journal of MedicinePlacebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
995 Citations2012Roy Fleischmann, Joel M. Kremer +8 more
In patients with active rheumatoid arthritis, tofacitinib monotherapy was associated with reductions in signs and symptoms of rheumatism and improvement in physical function and tofacit inib treatment wasassociated with elevations in low-density lipoprotein cholesterol levels and reductions in neutrophil counts.
New England Journal of MedicineTofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
915 Citations2012Ronald van Vollenhoven, Roy Fleischmann +12 more
In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.
Arthritis & RheumatismThe american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis
886 Citations1992Marc C. Hochberg, Rowland W. Chang +4 more
Revised criteria for global functional status in rheumatoid arthritis will be useful in describing the functional consequences of RA and a more detailed quantitative measure of physical disability should be used for optimal monitoring of patients' clinical status in office practice and clinical research.
New England Journal of MedicineBaricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
885 Citations2017Peter C. Taylor, Edward Keystone +15 more
New England Journal of MedicineTofacitinib versus Methotrexate in Rheumatoid Arthritis
753 Citations2014Eun Bong Lee, Roy Fleischmann +10 more
Tofacitinib monotherapy was superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting the progression of structural joint damage.
The LancetTofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
707 Citations2013Gerd R Burmester, Ricardo Blanco +12 more
In this treatment-refractory population, tofacitinib with methotrexate had rapid and clinically meaningful improvements in signs and symptoms of rheumatoid arthritis and physical function over 6 months with manageable safety.
Annals of the Rheumatic DiseasesEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
620 Citations2004L.B.A. van de Putte, Catherine Atkin +14 more
Adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function and was safe and well tolerated among patients with RA for whom previous DMARD treatment had failed.
Arthritis & RheumatismTofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
582 Citations2013Désirée van der Heijde, Yoshiya Tanaka +18 more
Data from this 12-month interim analysis demonstrate that tofacitinib inhibits progression of structural damage and improves disease activity in patients with RA who are receiving MTX.
Annals of Internal MedicineTofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
447 Citations2013Joel M. Kremer, Zhanguo Li +12 more
Arthritis & RheumatologyBaricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
423 Citations2016Roy Fleischmann, Michael Schiff +14 more
Baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis who had received no or minimal conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) and who were naive to biologic DMARDs is evaluated.
Arthritis & RheumatismPhase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
379 Citations2011Roy Fleischmann, Maurizio Cutolo +10 more
Tofacitinib monotherapy at a dose of ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 weeks and demonstrated a manageable safety profile.
Annals of the Rheumatic DiseasesLong-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
378 Citations2017Stanley Cohen, Yoshiya Tanaka +13 more
An integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA is reported, finding AEs were generally stable over time and no new safety signals were observed compared with previous tofacItinib reports.
The Journal of RheumatologySafety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
302 Citations2014J. Wollenhaupt, Joel C. Silverfield +12 more
Tofacitinib demonstrated consistent safety and persistent efficacy over 48 months in patients with RA, as measured by ACR response rate, DAS28-4-ESR, and HAQ-DI assessments.
Annals of the Rheumatic DiseasesReal-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
277 Citations2016Jeffrey R. Curtis, Fenglong Xie +3 more
The rate of zoster associated with tofacitinib was approximately double that observed in patients using biologics, and a composite outcome of HZ or HSV.
The LancetAdjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
272 Citations2013Josef S Smolen, Paul Emery +9 more
Treatment to a stable low disease activity target resulted in improved clinical, functional, and structural outcomes, with both adalimumab-continuation and methotrexate-monotherapy.
Arthritis Research & TherapyTofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
148 Citations2016Hisashi Yamanaka, Yoshiya Tanaka +7 more
Annals of the Rheumatic DiseasesAdalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
107 Citations2016Gerd R Burmester, Robert Landewé +5 more
This analysis confirms and expands the known safety profile of adalimumab and reports no additional safety risk of laboratory abnormalities, hepatitis B reactivation and pregnancy outcomes, including spontaneous abortions and birth defects.
Annals of the Rheumatic DiseasesForget personalised medicine and focus on abating disease activity
76 Citations2012Josef S Smolen, Daniel Aletaha
Three different lines of evidence are summarized suggesting that current biological therapies directed at different molecules or cells have similar efficacy in rheumatoid arthritis and target similar populations of patients; therefore, distinct biological effects of targeted therapies may not account for differences in response.
Annals of the Rheumatic DiseasesSAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years
38 Citations2018J. Wollenhaupt, Joel C. Silverfield +6 more
In patients with RA who remained in the LTE studies, tofacitinib (5 or 10 mg BID), with or without background csDMARDs, was associated with consistent safety through Month 114 and sustained clinical efficacy through Month 96.
Revista Brasileira de Reumatologia (English Edition)Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials
24 Citations2013Marina Amaral de Ávila Machado, Alessandra Almeida Maciel +6 more
Adalimumab efficacy was demonstrated in monotherapy and when associated to a DMARD, but the evidence for combined use is more robust than that for monotherapy, and the results of the meta-analyses of adverse events were not statistically significant.